References
- Tripathi P, Sigh BP, Arron N. Recombinant allergens-gateway to efficient diagnosis and therapy for atopic asthma and rhinitis. Indian J Allergy Immunol 2006; 20:41 - 51
- Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18:157 - 162
- Sutton BJ, Beavil RL, Beavil AJ. Inhibition of IgE-receptor interactions. Br Med Bull 2000; 56:1004 - 1018
- Dimov VV, Stokes JR, Casale TB. Immunomodulators in asthma therapy. Curr Allergy Asthma Rep 2009; 9:475 - 483
- Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev 2009; 61:256 - 262
- Saxon A, Zhu D, Zhang K, Allen LC, Kepley CL. Genetically engineered negative signalling molecules in the immunomodulation of allergic diseases. Curr Opin Allergy Clin Immunol 2004; 4:563 - 568
- Miescher SM, Horn MP, Pachlopnik JM, Baldi L, Vogel M, Stadler BM. Natural anti-FcepsilonRIalpha autoantibodies isolated from healthy donors and chronic idiopathic urticaria patients reveal a restricted repertoire and autoreactivity on human basophils. Hum Antibodies 2001; 10:119 - 126
- Peng P, Liu Q, Wang Q, Rector E, Ma Y, Warrington R. Novel IgE peptide-based vaccine prevents the increase of IgE and downregulates elevated IgE in rodents. Clin Exp Allergy 2007; 37:1040 - 1048
- Hamilton RG Jr, MacGlashan DW, Saini SS. IgE antibody-specific activity in human allergic disease. Immunol Res 2010; 47:273 - 284
- D'Amato G, Salzillo A, Piccolo A, D'Amato M, Liccardi G. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgEmediated) asthma. Ther Clin Risk Manag 2007; 3:613 - 619
- Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006; 100:1907 - 1917
- Wang MR, Zhang YX, Gao Q, Wu M, He MY. A fully human recombinant anti-IgE antibody 2009; (Patent application no: 200810032639.2, China)
- Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRI. Nature 2000; 406:259 - 266
- Qian W, Zhang X, Li B, Zhang D, Tong Q, Chen L, et al. Development and characterization of a novel anti-IgE monoclonal antibody. Biochem Biophys Res Commun 2010; 395:547 - 552
- Kim S, Lee J, Lee SJ, Lee HJ. Ultra-sensitive detection of IgE using biofunctionalized nanoparticle-enhanced SPR. Talanta 2010; 81:1755 - 1759
- Qiao CX, Lv M, Guo LM, Yu M, Li Y, Lin Z, et al. Inhibition of IgE activity to bind its high affinity receptor (FcεRIα) by mouse anti-IgE Cε3∼4 monoclonal antibody (QME5). Int J Biomed Sci 2009; 5:336 - 344
- He MY, Hamon M, Liu H, Corper AL, Taussig MJ. Effects of mutation at the D-JH junction on affinity, specificity and idiotypy of anti-progesterone antibody DB3. Protein Sci 2006; 15:2141 - 2148